<DOC>
	<DOCNO>NCT03022825</DOCNO>
	<brief_summary>This Phase II , open-label , single-arm , multicenter study intravesical BCG plus ALT-803 patient BCG unresponsive high grade non-muscle invasive bladder cancer ( NMIBC ) . All patient treat study receive via urinary catheter bladder , BCG plus ALT-803 weekly 6 consecutive week ( induction ) . Patients without disease progression Months 3 , 6 , 9 12 eligible continue BCG+ALT-803 treatment ( maintenance ) . The study duration 24 month .</brief_summary>
	<brief_title>QUILT-3.032 : A Multicenter Clinical Trial Intravesical Bacillus Calmette-Guerin ( BCG ) Combination With ALT-803 Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>Male female patient 18 year age old Histologic confirmation nonmuscle invasive bladder cancer transitional cell carcinoma highrisk subtype Absence resectable disease transurethral resection ( TURBT ) procedure ( residual carcinoma situ ( CIS ) acceptable ; patient T1 tumor must undergo repeat resection biopsy must include muscularis propria negative tumor cell ) BCGunresponsive disease define : ( ) Persistent highgrade disease recurrence within 6 month receive least two course intravesical BCG ( least five six induction dos least two three maintenance dos ) ; ( b ) T1 highgrade disease first evaluation follow induction BCG alone ( least 5 six induction dos ) Histologically confirm presence CIS Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Voluntary write informed consent HIPAA authorization agree comply protocolspecified procedure followup evaluation Recurrence &gt; 1 year last BCG instillation Current evidence muscle invasive disease Life expectancy &lt; 5 year Any follow clinical laboratory value time enrollment : ( 1 ) Absolute neutrophil count ( ANC ) &lt; 800/µL ( 2 ) Platelets &lt; 50,000/µL Liver function abnormality indicate ongoing hepatic enzyme elevation ( AST ALT ) &gt; 2 time upper limit normal ( ULN ) Renal insufficiency indicate creatinine level &gt; 3 time ULN Evidence muscleinvasive bladder cancer regional and/or distant metastasis New York Heart Association ( NYHA ) Class III IV heart failure clinical sign severe cardiac dysfunction Symptomatic congestive heart failure ( CHF ) , severe/unstable angina pectoris , myocardial infarction within 6 month prior study entry History evidence uncontrollable central nervous system ( CNS ) disease Active systemic infection require parenteral antibiotic therapy . All prior infection must resolve follow optimal therapy Concurrent febrile illness , active urinary tract infection , active tuberculosis , history hypotension anaphylactic reaction Ongoing chronic systemic steroid therapy require ( &gt; 10 mg oral prednisone daily equivalent ) Women pregnant nursing . Female patient childbearing potential must negative pregnancy test agree use adequate contraception duration trial . Concurrent use investigational agent Other illness condition , include laboratory abnormality , opinion investigator would exclude patient participate study . This include , limited , serious medical condition psychiatric illness likely interfere participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>BCG</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>interleukin-15</keyword>
	<keyword>intravesical</keyword>
	<keyword>non-muscle invasive</keyword>
</DOC>